Chapter 3: The hypothalamus, hormones, and hunger: alterations in human obesity and illness

Progress in Brain Research

Volumn 153, Issue , 2006, Pages 57-73

  Goldstone, Anthony P ^a  

^a MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

Author keywords

appetite; ghrelin; hypothalamus; obesity; oxyntomodulin; pancreatic polypeptide; Prader Willi syndrome; PYY

Indexed keywords

AGOUTI RELATED PROTEIN; APPETITE STIMULANT; GASTROINTESTINAL HORMONE; GHRELIN; INTESTINAL PEPTIDE; NEUROPEPTIDE Y; OXYNTOMODULIN; OXYTOCIN; PANCREAS POLYPEPTIDE; PEPTIDE; UNCLASSIFIED DRUG; HORMONE;

ANOREXIA; APPETITE; CHROMOSOME 15Q; CHRONIC DISEASE; FOOD INTAKE; HUMAN; HUNGER; HYPOTHALAMUS; INSULIN SENSITIVITY; METABOLIC REGULATION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; POSITRON EMISSION TOMOGRAPHY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STOMACH BYPASS; BRAIN MAPPING; DIAGNOSTIC IMAGING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

BRAIN MAPPING; DIAGNOSTIC IMAGING; HORMONES; HUMANS; HUNGER; HYPOTHALAMUS; OBESITY;

EID: 33746288477     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(06)53003-1     Document Type: Review

References (127)

1. Adrian T.E., Savage A.P., Sagor G.R., Allen J.M., Bacarese-Hamilton A.J., Tatemoto K., Polak J.M., and Bloom S.R. Effect of peptide YY on gastric, pancreatic, and biliary function in humans. Gastroenterology 89 (1985) 494-499
2. Allen J.M., Fitzpatrick M.L., Yeats J.C., Darcy K., Adrian T.E., and Bloom S.R. Effects of peptide YY and neuropeptide Y on gastric emptying in man. Digestion 30 (1984) 255-262
3. Andersson U., Filipsson K., Abbott C.R., Woods A., Smith K., Bloom S.R., Carling D., and Small C.J. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279 (2004) 12005-12008
4. Asakawa A., Inui A., Yuzuriha H., Ueno N., Katsuura G., Fujimiya M., Fujino M.A., Niijima A., Meguid M.M., and Kasuga M. Characterization of the effects of pancreatic polypeptide in the regulation of energy balance. Gastroenterology 124 (2003) 1325-1336
5. Avenell A., Broom J., Brown T.J., Poobalan A., Aucott L., Stearns S.C., Smith W.C., Jung R.T., Campbell M.K., and Grant A.M. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol. Assess. 8 (2004) 1-182
6. Badman M.K., and Flier J.S. The gut and energy balance: visceral allies in the obesity wars. Science 307 (2005) 1909-1914
7. Baggio L.L., Huang Q., Brown T.J., and Drucker D.J. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 127 (2004) 546-558
8. Batterham R.L., Cohen M.A., Ellis S.M., Le Roux C.W., Withers D.J., Frost G.S., Ghatei M.A., and Bloom S.R. Inhibition of food intake in obese subjects by peptide YY3-36. N. Engl. J. Med. 349 (2003) 941-948
9. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., Wren A.M., Brynes A.E., Low M.J., Ghatei M.A., Cone R.D., and Bloom S.R. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418 (2002) 650-654
10. Batterham R.L., Le Roux C.W., Cohen M.A., Park A.J., Ellis S.M., Patterson M., Frost G.S., Ghatei M.A., and Bloom S.R. Pancreatic polypeptide reduces appetite and food intake in humans. J. Clin. Endocrinol. Metab. 88 (2003) 3989-3992
11. Bell C.G., Walley A.J., and Froguel P. The genetics of human obesity. Nat. Rev. Genet. 6 (2005) 221-234
12. Berntson G.G., Zipf W.B., O'Dorisio T.M., Hoffman J.A., and Chance R.E. Pancreatic polypeptide infusions reduce food intake in Prader-Willi syndrome. Peptides 14 (1993) 497-503
13. Berthoud H. Mind versus metabolism in the control of food intake and energy balance. Physiol. Behav. 81 (2004) 781-793
14. Bewick G.A., Gardiner J.V., Dhillo W.S., Kent A.S., White N.E., Webster Z., Ghatei M.A., and Bloom S.R. Post-embryonic ablation of AgRP neurons in mice leads to a lean, hypophagic phenotype. FASEB J. 19 (2005) 1680-1682
15. Bray G.A. Drug treatment of obesity. Baillieres Best Pract. Res. Clin. Endocrinol. Metab. 13 (1999) 131-148
16. Bray G.A. Afferent signals regulating food intake. Proc. Nutr. Soc. 59 (2000) 373-384
17. Challis B.G., Coll A.P., Yeo G.S., Pinnock S.B., Dickson S.L., Thresher R.R., Dixon J., Zahn D., Rochford J.J., White A., Oliver R.L., Millington G., Aparicio S.A., Colledge W.H., Russ A.P., Carlton M.B., and O'Rahilly S. Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY(3-36). Proc. Natl. Acad. Sci. USA 101 (2004) 4695-4700
18. Chamberlain S.J., Johnstone K.A., DuBose A.J., Simon T.A., Bartolomei M.S., Resnick J.L., and Brannan C.I. Evidence for genetic modifiers of postnatal lethality in PWS-IC deletion mice. Hum. Mol. Genet. 13 (2004) 2971-2979
19. Cohen M.A., Ellis S.M., Le Roux C.W., Batterham R.L., Park A., Patterson M., Frost G.S., Ghatei M.A., and Bloom S.R. Oxyntomodulin suppresses appetite and reduces food intake in humans. J. Clin. Endocrinol. Metab. 88 (2003) 4696-4701
20. Cox J.E., and Randich A. Enhancement of feeding suppression by PYY(3-36) in rats with area postrema ablations. Peptides 25 (2004) 985-989
21. Dakin C.L., Small C.J., Batterham R.L., Neary N.M., Cohen M.A., Patterson M., Ghatei M.A., and Bloom S.R. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 145 (2004) 2687-2695
22. Date Y., Murakami N., Toshinai K., Matsukura S., Niijima A., Matsuo H., Kangawa K., and Nakazato M. The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats. Gastroenterology 123 (2002) 1120-1128
23. De Graaf C., Blom W.A.M., Smeets P.A.M., Stafleu A., and Hendriks H.F.J. Biomarkers of satiation and satiety. Am. J. Clin. Nutr. 79 (2004) 946-961
24. Deitel M. The International Obesity Task Force and "globesity". Obes. Surg. 12 (2002) 613-614
25. Del Parigi A., Gautier J.F., Chen K., Salbe A.D., Ravussin E., Reiman E., and Tataranni P.A. Neuroimaging and obesity: mapping the brain responses to hunger and satiation in humans using positron emission tomography. Ann. N.Y. Acad. Sci. 967 (2002) 389-397
26. Delparigi A., Chen K., Salbe A.D., Hill J.O., Wing R.R., Reiman E.M., and Tataranni P.A. Persistence of abnormal neural responses to a meal in postobese individuals. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 370-377
27. Department of Health (2004) Health Survey for England 2003 www.dh.gov.uk/assetRoot/04/09/89/11/04098911.pdf Vol. 2: 147.
28. Di Marzo V., and Matias I. Endocannabinoid control of food intake and energy balance. Nat. Neurosci. 8 (2005) 585-589
29. Druce M.R., Wren A.M., Park A.J., Milton J.E., Patterson M., Frost G., Ghatei M.A., Small C., and Bloom S.R. Ghrelin increases food intake in obese as well as lean subjects. Int. J. Obes. Relat. Metab. Disord. 29 (2005) 1130-1136
30. Everitt B.J., Parkinson J.A., Olmstead M.C., Arroyo M., Robledo P., and Robbins T.W. Associative processes in addiction and reward. The role of amygdala-ventral striatal subsystems. Ann. N.Y. Acad. Sci. 877 (1999) 412-438
31. Fieldstone A., Zipf W.B., Sarter M.F., and Berntson G.G. Food intake in Prader-Willi syndrome and controls with obesity after administration of a benzodiazepine-receptor agonist. Obes. Res. 6 (1998) 29-33
32. Flier J.S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116 (2004) 337-350
33. Fox R. Overweight children. Circulation 108 (2003) e9071
34. Fronczek R., Lammers G.J., Balesar R., Unmehopa U.A., and Swaab D.F. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 90 (2005) 5466-5470
35. Fulton S., Woodside B., and Shizgal P. Modulation of brain reward circuitry by leptin. Science 287 (2000) 125-128
36. Goldstone A.P. Prader-Willi syndrome: advances in its genetics, pathophysiology and treatment. Trends Endocrinol. Metab. 15 (2004) 12-20
37. Goldstone A.P., Morgan I., Mercer J.G., Morgan D.G., Moar K.M., Ghatei M.A., and Bloom S.R. Effect of leptin on hypothalamic GLP-1 peptide and brain-stem pre-proglucagon mRNA. Biochem. Biophys. Res. Commun. 269 (2000) 331-335
38. Goldstone A.P., Patterson M., Kalingag N., Ghatei M.A., Brynes A.E., Bloom S.R., Grossman A.B., and Korbonits M. Fasting and post-prandial hyperghrelinemia in Prader-Willi syndrome is partially explained by hypoinsulinemia, and is not due to peptide YY 3-36 deficiency or seen in hypothalamic obesity due to craniopharyngioma. J. Clin. Endocrinol. Metab. 90 (2005) 2681-2690
39. Goldstone A.P., Thomas E.L., Brynes A.E., Bell J.D., Frost G., Saeed N., Hajnal J.V., Howard J.K., Holland A., and Bloom S.R. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J. Clin. Endocrinol. Metab. 86 (2001) 4330-4338
40. Goldstone A.P., Thomas E.L., Brynes A.E., Castroman G., Edwards R., Ghatei M.A., Frost G., Holland A.J., Grossman A.B., Korbonits M., Bloom S.R., and Bell J.D. Elevated fasting plasma ghrelin in Prader-Willi-syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance. J. Clin. Endocrinol. Metab. 89 (2004) 1718-1726
41. Goldstone A.P., Unmehopa U.A., Bloom S.R., and Swaab D.F. Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects. J. Clin. Endocrinol. Metab. 87 (2002) 927-937
42. Goldstone A.P., Unmehopa U.A., and Swaab D.F. Hypothalamic growth hormone-releasing hormone (GHRH) cell number is increased in human illness, but is not reduced in Prader-Willi syndrome or obesity (erratum in Clin. Endocrinol. 59, 266, 2003). Clin. Endocrinol. (Oxf.) 58 (2003) 743-755
43. Halatchev I.G., Ellacott K.L., Fan W., and Cone R.D. Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. Endocrinology 145 (2004) 2585-2590
44. Halford J.C., Harrold J.A., Lawton C.L., and Blundell J.E. Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets 6 (2005) 201-213
45. Harris G.C., Wimmer M., and Jones G.A. A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437 (2005) 556-559
46. Hill J.O., and Peters J.C. Environmental contributions to the obesity epidemic. Science 280 (1998) 1371-1374
47. Hinton, E.C., Holland, A.J., Gellatly, M.S., Soni, S., Patterson, M., Ghatei, M.A. and Owen, A.M. (2005) Neural representations of hunger and satiety in Prader-Willi syndrome. Int. J. Obes., Vol. 30, 313-321.
48. Hinton E.C., Parkinson J.A., Holland A.J., Arana F.S., Roberts A.C., and Owen A.M. Neural contributions to the motivational control of appetite in humans. Eur. J. Neurosci. 20 (2004) 1411-1418
49. Hoffman C.J., Aultman D., and Pipes P. A nutrition survey of and recommendations for individuals with Prader-Willi syndrome who live in group homes. J. Am. Diet. Assoc. 92 (1992) 823-830, 833
50. Holland A.J., Treasure J., Coskeran P., Dallow J., Milton N., and Hillhouse E. Measurement of excessive appetite and metabolic changes in Prader-Willi syndrome. Int. J. Obes. 17 (1993) 527-532
51. Holm V.A., Cassidy S.B., Butler M.G., Hanchett J.M., Greenswag L.R., Whitman B.Y., and Greenberg F. Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91 (1993) 398-402
52. Holsen, L., Zarcone, J., Anderson, M., Young, J., Butler, M.G., Thompson, T. and Savage, C. (2004) Abnormal food motivation in Prader-Willi syndrome: relationship between neural dysfunction and obesity using fMRI. Abstracts 26th USA Prader-Willi Syndrome Conference, Sandusky, Ohio.
53. Holsen L.M., Zarcone J.R., Thompson T.I., Brooks W.M., Anderson M.F., Ahluwalia J.S., Nollen N.L., and Savage C.R. Neural mechanisms underlying food motivation in children and adolescents. Neuroimage 27 (2005) 669-676
54. James, G.A., Miller, J.L., Couch, J., Goldstone, A.P., He, G., Driscoll, D.J. and Liu, Y. (2006) Heightened orbitofrontal BOLD response to food stimuli in Prader-Willi patients. Abstracts 12th Annual Meeting of the Organization for Human Brain Mapping, Florence, Italy.
55. Jo Y.H., Chen Y.J., Chua Jr. S.C., Talmage D.A., and Role L.W. Integration of endocannabinoid and leptin signaling in an appetite-related neural circuit. Neuron 48 (2005) 1055-1066
56. Killgore W.D., Young A.D., Femia L.A., Bogorodzki P., Rogowska J., and Yurgelun-Todd D.A. Cortical and limbic activation during viewing of high- versus low-calorie foods. Neuroimage 19 (2003) 1381-1394
57. Kimm S.Y., and Obarzanek E. Childhood obesity: a new pandemic of the new millennium. Pediatrics 110 (2002) 1003-1007
58. Kishi T., and Elmquist J.K. Body weight is regulated by the brain: a link between feeding and emotion. Mol. Psychiatry 10 (2005) 132-146
59. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., and Nathan D.M. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
60. Koplan J.P., and Dietz W.H. Caloric imbalance and public health policy. JAMA 282 (1999) 1579-1581
61. Korbonits M., Goldstone A.P., Gueorguiev M., and Grossman A.B. Ghrelin - a hormone with multiple functions. Front. Neuroendocrinol. 25 (2004) 27-68
62. Kringelbach M.L. Food for thought: hedonic experience beyond homeostasis in the human brain. Neuroscience 126 (2004) 807-819
63. Kringelbach M.L., and Rolls E.T. The functional neuroanatomy of the human orbitofrontal cortex: evidence from neuroimaging and neuropsychology. Prog. Neurobiol. 72 (2004) 341-372
64. Kuo, Y.T., Parkinson, J.R., Herlihy, A.H., So, P.W., Small, C.J., Bloom, S.R. and Bell, J.D. (2004) Imaging appetite in vivo with manganese-enhanced MRI (MEMRI). Abstracts ISMRM 13th Scientific Meeting, Miami Beach, FL, USA.
65. LaBar K.S., Gitelman D.R., Parrish T.B., Kim Y.H., Nobre A.C., and Mesulam M.M. Hunger selectively modulates corticolimbic activation to food stimuli in humans. Behav. Neurosci. 115 (2001) 493-500
66. Lassmann V., Vague P., Vialettes B., and Simon M.C. Low plasma levels of pancreatic polypeptide in obesity. Diabetes 29 (1980) 428-430
67. Le Roux C.W., Batterham R.L., Aylwin S.J., Patterson M., Borg C.M., Wynne K.J., Kent A., Vincent R.P., Gardiner J., Ghatei M.A., and Bloom S.R. Attenuated peptide YY release in obese subjects is associated with reduced satiety. Endocrinology 147 (2006) 3-8
68. Le Roux C.W., and Bloom S.R. Why do patients lose weight after Roux-en-Y gastric bypass?. J. Clin. Endocrinol. Metab. 90 (2005) 591-592
69. Le Roux C.W., Neary N.M., Halsey T.J., Small C.J., Martinez-Isla A.M., Ghatei M.A., Theodorou N.A., and Bloom S.R. Ghrelin does not stimulate food intake in patients with surgical procedures involving vagotomy. J. Clin. Endocrinol. Metab. 90 (2005) 4521-4524
70. Le Roux C.W., Patterson M., Vincent R.P., Hunt C., Ghatei M.A., and Bloom S.R. Postprandial plasma ghrelin is suppressed proportional to meal calorie content in normal weight but not obese subjects. J. Clin. Endocrinol. Metab. 90 (2005) 1068-1071
71. Leibowitz S.F., and Alexander J.T. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol. Psychiatry 44 (1998) 851-864
72. Lieverse R.J., Jansen J.B., Masclee A.M., and Lamers C.B. Satiety effects of cholecystokinin in humans. Gastroenterology 106 (1994) 1451-1454
73. Liu Y., Gao J.H., Liu H.L., and Fox P.T. The temporal response of the brain after eating revealed by functional MRI. Nature 405 (2000) 1058-1062
74. Magarey A.M., Daniels L.A., Boulton T.J., and Cockington R.A. Predicting obesity in early adulthood from childhood and parental obesity. Int. J. Obes. Relat. Metab. Disord. 27 (2003) 505-513
75. Martin N.M., Small C.J., Sajedi A., Patterson M., Ghatei M.A., and Bloom S.R. Pre-obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) but resistant to ghrelin. Int. J. Obes. Relat. Metab. Disord. 28 (2004) 886-893
76. Matsuda M., Liu Y., Mahankali S., Pu Y., Mahankali A., Wang J., DeFronzo R.A., Fox P.T., and Gao J.H. Altered hypothalamic function in response to glucose ingestion in obese humans. Diabetes 48 (1999) 1801-1806
77. Miller, J., Kranzler, J., Hatfield, A., Mueller, O.T., Theriaque, D.W., Goldstone, A.P., Shuster, J.J. and Driscoll, D.J. (2005) Cognitive and behavioral findings in Prader-Willi syndrome and early onset morbid obesity. Abstracts 27th USA Prader-Willi Syndrome Conference, Orlando, FL.
78. Morris J.S., and Dolan R.J. Involvement of human amygdala and orbitofrontal cortex in hunger-enhanced memory for food stimuli. J. Neurosci. 21 (2001) 5304-5310
79. Murray C.D., Martin N.M., Patterson M., Taylor S., Ghatei M.A., Kamm M.A., Johnston C., Bloom S.R., and Emmanuel A.V. Ghrelin enhances gastric emptying in diabetic gastroparesis: a double-blind, placebo-controlled, cross-over study. Gut 54 (2005) 1693-1698
80. Must A. Does overweight in childhood have an impact on adult health?. Nutr. Rev. 61 (2003) 139-142
81. Naleid A.M., Grace M.K., Cummings D.E., and Levine A.S. Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens. Peptides 26 (2005) 2274-2279
82. Naslund E., Bogefors J., Skogar S., Gryback P., Jacobsson H., Holst J.J., and Hellstrom P.M. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am. J. Physiol. 277 (1999) R910-R916
83. Neary N.M., Goldstone A.P., and Bloom S.R. Appetite regulation: from the gut to the hypothalamus. Clin. Endocrinol. (Oxf.) 60 (2004) 153-160
84. Neary N.M., Small C.J., Druce M.R., Park A.J., Ellis S.M., Semjonous N.M., Dakin C.L., Filipsson K., Wang F., Kent A.S., Frost G.S., Ghatei M.A., and Bloom S.R. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Endocrinology 146 (2005) 5120-5127
85. Neary N.M., Small C.J., Wren A.M., Lee J.L., Druce M.R., Palmieri C., Frost G.S., Ghatei M.A., Coombes R.C., and Bloom S.R. Ghrelin increases energy intake in cancer patients with impaired appetite: acute, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 89 (2004) 2832-2836
86. Nicholls R.D., and Knepper J.L. Genome organization, function, and imprinting in Prader-Willi and Angelman syndromes. Annu. Rev. Genomics Hum. Genet. 2 (2002) 153-175
87. O'Rahilly S., Farooqi I.S., Yeo G.S., and Challis B.G. Minireview: human obesity-lessons from monogenic disorders. Endocrinology 144 (2003) 3757-3764
88. Perusse L., Rankinen T., Zuberi A., Chagnon Y.C., Weisnagel S.J., Argyropoulos G., Walts B., Snyder E.E., and Bouchard C. The human obesity gene map: the 2004 update. Obes. Res. 13 (2005) 381-490
89. Riccardi G., Capaldo B., and Vaccaro O. Functional foods in the management of obesity and type 2 diabetes. Curr. Opin. Clin. Nutr. Metab. Care 8 (2005) 630-635
90. Roth C.L., Enriori P.J., Harz K., Woelfle J., Cowley M.A., and Reinehr T. Peptide YY Is a regulator of energy homeostasis in obese children before and after weight loss. J. Clin. Endocrinol. Metab. 90 (2005) 6386-6391
91. Sainsbury A., Schwarzer C., Couzens M., Fetissov S., Furtinger S., Jenkins A., Cox H.M., Sperk G., Hokfelt T., and Herzog H. Important role of hypothalamic Y2 receptors in body weight regulation revealed in conditional knockout mice. Proc. Natl. Acad. Sci. USA 99 (2002) 8938-8943
92. Shapira N.A., Lessig M.C., He G.A., James G.A., Driscoll D.J., and Liu Y. Satiety dysfunction in Prader-Willi syndrome demonstrated by fMRI. J. Neurol. Neurosurg. Psych. 76 (2005) 260-262
93. Shapira N.A., Lessig M.C., Lewis M.H., Goodman W.K., and Driscoll D.J. Effects of topiramate in adults with Prader-Willi syndrome. Am. J. Ment. Retard. 109 (2004) 301-309
94. Shimizu Y., Nagaya N., Isobe T., Imazu M., Okumura H., Hosoda H., Kojima M., Kangawa K., and Kohno N. Increased plasma ghrelin level in lung cancer cachexia. Clin. Cancer Res. 9 (2003) 774-778
95. Small C.J., and Bloom S.R. Gut hormones as peripheral anti-obesity targets. Curr. Drug Targets CNS Neurol. Disord. 3 (2004) 379-388
96. Smeets P.A., De Graaf C., Stafleu A., Van Osch M.J., and Van der Grond J. Functional magnetic resonance imaging of human hypothalamic responses to sweet taste and calories. Am. J. Clin. Nutr. 82 (2005) 1011-1016
97. Smeets P.A., De Graaf C., Stafleu A., Van Osch M.J., and Van der Grond J. Functional MRI of human hypothalamic responses following glucose ingestion. Neuroimage 24 (2005) 363-368
98. Speiser P.W., Rudolf M.C., Anhalt H., Camacho-Hubner C., Chiarelli F., Eliakim A., Freemark M., Gruters A., Hershkovitz E., Iughetti L., Krude H., Latzer Y., Lustig R.H., Pescovitz O.H., Pinhas-Hamiel O., Rogol A.D., Shalitin S., Sultan C., Stein D., Vardi P., Werther G.A., Zadik Z., Zuckerman-Levin N., and Hochberg Z. Childhood obesity. J. Clin. Endocrinol. Metab. 90 (2005) 1871-1887
99. Spiegel A., Nabel E., Volkow N., Landis S., and Li T.K. Obesity on the brain. Nat. Neurosci. 8 (2005) 552-553
100. Stephan E., Pardo J.V., Faris P.L., Hartman B.K., Kim S.W., Ivanov E.H., Daughters R.S., Costello P.A., and Goodale R.L. Functional neuroimaging of gastric distention. J. Gastrointest. Surg. 7 (2003) 740-749
101. Sturm K., MacIntosh C.G., Parker B.A., Wishart J., Horowitz M., and Chapman I.M. Appetite, food intake, and plasma concentrations of cholecystokinin, ghrelin, and other gastrointestinal hormones in undernourished older women and well-nourished young and older women. J. Clin. Endocrinol. Metab. 88 (2003) 3747-3755
102. Swaab D.F. Infundibular nucleus (arcuate nucleus), subventricular nucleus and median eminence. In: Aminoff M.J., Boller F., and Swaab D.F. (Eds). The Human Hypothalamus: Basic and Clinical Aspects, Part I Vol. 79 (2003) (3rd Series Vol. 1)
103. Swaab D.F. Lateral hypothalamic area (LHA), including the perifornical area and intermediate hypothalamic area (IHA). In: Aminoff M.J., Boller F., and Swaab D.F. (Eds). The Human Hypothalamus: Basic and Clinical Aspects, Part I Vol. 79 (2003) (3rd Series Vol. 1)
104. Swaab D.F. Supraoptic and paraventricular nucleus. In: Aminoff M.J., Boller F., and Swaab D.F. (Eds). The Human Hypothalamus: Basic and Clinical Aspects, Part I Vol. 79 (2003) (3rd Series Vol. 1)
105. Swaab D.F., Purba J.S., and Hofman M.A. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of five cases. J. Clin. Endocrinol. Metab. 80 (1995) 573-579
106. Szczypka M.S., Rainey M.A., and Palmiter R.D. Dopamine is required for hyperphagia in Lep(ob/ob) mice. Nat. Genet. 25 (2000) 102-104
107. Tan T.M., Vanderpump M., Khoo B., Patterson M., Ghatei M.A., and Goldstone A.P. Somatostatin infusion lowers plasma ghrelin without reducing appetite in adults with Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 89 (2004) 4162-4165
108. Tataranni P.A., Gautier J.F., Chen K.W., Uecker A., Bandy D., Salbe A.D., Pratley R.E., Lawson M., Reiman E.M., and Ravussin E. Neuroanatomical correlates of hunger and satiation in humans using positron emission tomography. Proc. Natl. Acad. Sci. USA 96 (1999) 4569-4574
109. Tataranni, P.A., Chen, K., Salbe, A.D., Reiman, E.M. and Del Parigi, A. (2004) Neuroimaging evidence implicates the human hypothalamus in monitoring the relative energy content of a meal. Abstracts 86th Annual Meeting of the American Endocrine Society, New Orleans, OR19-3.
110. Tataranni P.A., and Delparigi A. Functional neuroimaging: a new generation of human brain studies in obesity research. Obes. Rev. 4 (2003) 229-238
111. Tataranni P.A., Harper I.T., Snitker S., Del Parigi A., Vozarova B., Bunt J., Bogardus C., and Ravussin E. Body weight gain in free-living Pima Indians: effect of energy intake vs. expenditure. Int. J. Obes. Relat. Metab. Disord. 27 (2003) 1578-1583
112. Thibault H., and Rolland-Cachera M.F. Prevention strategies of childhood obesity. Arch. Pediatr. 10 (2003) 1100-1108
113. Turton M.D., O'Shea D., Gunn I., Beak S.A., Edwards C.M.B., Meeran K., Choi S.J., Taylor G.M., Heath M.M., Lambert P.D., Wilding J.P.H., Smith D.M., Ghatei M.A., Herbert J., and Bloom S.R. A role for glucagon-like peptide 1 in the central regulation of feeding. Nature 379 (1996) 69-72
114. Van den Berghe G. Novel insights into the neuroendocrinology of critical illness. Eur. J. Endocrinol. 143 (2000) 1-13
115. Verdich C., Flint A., Gutzwiller J.P., Naslund E., Beglinger C., Hellstrom P.M., Long S.J., Morgan L.M., Holst J.J., and Astrup A. A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans. J. Clin. Endocrinol. Metab. 86 (2001) 4382-4389
116. Volkow N.D., and Wise R.A. How can drug addiction help us understand obesity?. Nat. Neurosci. 8 (2005) 555-560
117. Wallace B.A., Ashkan K., and Benabid A.L. Deep brain stimulation for the treatment of chronic, intractable pain. Neurosurg. Clin. N. Am. 15 (2004) 343-357
118. Wang G.J., Volkow N.D., Logan J., Pappas N.R., Wong C.T., Zhu W., Netusil N., and Fowler J.S. Brain dopamine and obesity. Lancet 357 (2001) 354-357
119. Wellman P.J. Modulation of eating by central catecholamine systems. Curr. Drug Targets 6 (2005) 191-199
120. Whittington J., Holland A., Webb T., Butler J., Clarke D., and Boer H. Relationship between clinical and genetic diagnosis of Prader-Willi syndrome. J. Med. Genet. 39 (2002) 926-932
121. Whittington J.E., Holland A.J., Webb T., Butler J., Clarke D., and Boer H. Population prevalence and estimated birth incidence and mortality rate for people with Prader-Willi syndrome in one UK Health Region. J. Med. Genet. 38 (2001) 792-798
122. Wren A.M., Seal L.J., Cohen M.A., Brynes A.E., Frost G.S., Murphy K.G., Dhillo W.S., Ghatei M.A., and Bloom S.R. Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86 (2001) 5992-5995
123. Wynne K., Giannitsopoulou K., Small C.J., Patterson M., Frost G., Ghatei M.A., Brown E.A., Bloom S.R., and Choi P. Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: a randomized, placebo-controlled trial. J. Am. Soc. Nephrol. 16 (2005) 2111-2118
124. Wynne K., Park A.J., Small C.J., Patterson M., Ellis S.M., Murphy K.G., Wren A.M., Frost G.S., Meeran K., Ghatei M.A., and Bloom S.R. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 54 (2005) 2390-2395
125. Young A.A. Obesity: a peptide YY-deficient, but not peptide YY-resistant, state. Endocrinology 147 (2006) 1-2
126. Zipf W.B., O'Dorisio T.M., and Berntson G.G. Short-term infusion of pancreatic polypeptide: effect on children with Prader-Willi syndrome. Am. J. Clin. Nutr. 51 (1990) 162-166
127. Zipf W.B., O'Dorisio T.M., Cataland S., and Sotos J. Blunted pancreatic polypeptide responses in children with obesity of Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 52 (1981) 1264-1266